Skip to main content
Top
Published in: Cardiology and Therapy 2/2020

Open Access 01-12-2020 | Direct Oral Anticoagulant | Original Research

Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment

Authors: Marcel Slavenburg, Janneke H. van den Bent, Thierry Barten, Margje Reijs-Scheijgrond, Constance de Koning

Published in: Cardiology and Therapy | Issue 2/2020

Login to get access

Abstract

Introduction

This study was designed to gain insight into the treatment experiences and expectations of patients with atrial fibrillation (AF) who were treated with vitamin K antagonists (VKA) or recently switched from VKA treatment to direct oral anticoagulant (DOAC) therapy. Little is known about the perceptions and expectations of patients with AF who are being prescribed oral anticoagulants (OACs), leading to different expectations of patient and doctor of their respective roles in disease management between the doctor [general practitioner (GP) or cardiologist] and patient on their respective roles in disease management.

Methods

A market research study was conducted consisting of two phases: (1) qualitative research (n = 16) in which in-depth interviews were conducted; and (2) quantitative research (n = 101), using a conjoint analysis.

Results

Patients reported that the three most important aspects of OAC treatment were (in order of priority) reduced risk of blood clots/stroke, low bleeding risk, and not having to use a thrombosis service. Only 12% of VKA-treated patients were familiar with DOAC, although 52% were open to switching when presented with a DOAC profile.

Conclusions

GPs and patients are waiting for the other to mention issues surrounding AF treatment such as switching, use of thrombosis service, and number of pills to take first. The perceptions and experiences of patients with AF regarding their disease and treatment highly influence the decisions GPs make, together with these patients, as well as considerations that patients have regarding their treatment; GPs need to be aware of their AF patients’ perceptions and experiences with their condition and medication’ in order to facilitate discussions with patients and improve clinical outcomes.
Footnotes
1
Upon request, sponsor name would have been released after completion of research.
 
Literature
1.
go back to reference IPSOS. GPs—embrace independent NOAC prescription in the Netherlands. 2019. IPSOS. GPs—embrace independent NOAC prescription in the Netherlands. 2019.
2.
go back to reference NHG-werkgroep Atriumfibrilleren. NHG-Standaard Atriumfibrilleren. Huisarts Wet. 2017;60(9):460. NHG-werkgroep Atriumfibrilleren. NHG-Standaard Atriumfibrilleren. Huisarts Wet. 2017;60(9):460.
4.
go back to reference Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.CrossRef Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.CrossRef
5.
go back to reference Lip GYH, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49:2933–44.CrossRef Lip GYH, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49:2933–44.CrossRef
6.
go back to reference Deitelzweig S, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33:1745–54.CrossRef Deitelzweig S, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33:1745–54.CrossRef
7.
go back to reference Halvorsen S, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3:28–36.CrossRef Halvorsen S, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3:28–36.CrossRef
8.
go back to reference Li X, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072–82.CrossRef Li X, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072–82.CrossRef
9.
go back to reference Yao X, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.CrossRef Yao X, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.CrossRef
10.
go back to reference Graham DJ, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132:596–604.CrossRef Graham DJ, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132:596–604.CrossRef
11.
go back to reference Adams WC. Conducting semi-structured interviews. In: Newcomer KE, et al., editors. Handbook of practical program evaluation. 4th ed. New York: Wiley Online Library; 2019. Adams WC. Conducting semi-structured interviews. In: Newcomer KE, et al., editors. Handbook of practical program evaluation. 4th ed. New York: Wiley Online Library; 2019.
12.
go back to reference SKIM. Understanding patient needs in Atrial Fibrillation. Patient understanding 101. 2019. SKIM. Understanding patient needs in Atrial Fibrillation. Patient understanding 101. 2019.
Metadata
Title
Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment
Authors
Marcel Slavenburg
Janneke H. van den Bent
Thierry Barten
Margje Reijs-Scheijgrond
Constance de Koning
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 2/2020
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-020-00173-8

Other articles of this Issue 2/2020

Cardiology and Therapy 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.